
CLAIMS


WHAT IS CLAIMED IS

1. A composition comprising a therapeutically effective amount of a compound of formula (I)



(I),

or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a compound of formula (II),



(II),

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

2. The composition of claim 1 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof, is between ~~about~~ 1:3 and ~~about~~ 3:1.

3. The composition of claim 2 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof, is between ~~about~~ 1:2.5 and ~~about~~ 2.5:1.

4. The composition of claim 3 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof is ~~about~~ 1:1.

5. The composition of claim 3 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof, is ~~about~~ 1:2.5.

6. The composition of claim 3 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof, is ~~about~~ 2.5:1.

7. The composition of claim 1 further comprising one or two additional compounds having anti-HCV activity.

8. The composition of claim 7 wherein at least one of the additional compounds is an interferon or a ribavirin.

9. The composition of claim 8 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, interferon lambda, pegylated interferon lambda, and lymphoblastoid interferon tau.

10. A use of a composition of claim 1 in the manufacture of a medicament for treating an HCV infection in a patient..

11. The use of claim 10 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof, is between ~~about~~ 1:3 and ~~about~~ 3:1.

12. The use of claim 11 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof, is between ~~about~~ 1:2.5 and ~~about~~ 2.5:1.

13. The useof claim 12 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof is ~~about~~ 1:1.

14. The use of claim 12 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof, is ~~about~~ 1:2.5.

15. The use of claim 12 wherein the ratio of the compound of formula (I), or a pharmaceutically acceptable salt thereof, to the compound of formula (II), or a pharmaceutically acceptable salt thereof, is ~~about~~ 2.5:1.

16. The use of claim 10 further comprising administering one or two additional compound having anti-HCV activity prior to, after or simultaneously with the composition of claim 1.

17. The use of claim 16 wherein at least one of the additional compounds is an interferon or a ribavirin.

18. The use of claim 17 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, interferon lambda, pegylated interferon lambda, and lymphoblastoid interferon tau.